Symberix Email Format
Biotechnology ResearchNorth Carolina, United States2-10 Employees
Symberix, an early-stage spin-out of the University of North Carolina at Chapel Hill, aims to improve human health by pioneering the development of symbiotic drugs that work by controlling bacteria without killing them. Symberix’s scientific founder, Matthew Redinbo, PhD, was the first to demonstrate the feasibility of therapeutically controlling the mammalian microbiome with small-molecule symbiotic drugs. Based on this breakthrough research, the company is advancing a first-in-class approach to improve the treatment of serious lower gastrointestinal (GI) diseases as well as mitigate the debilitating lower GI side effects associated with various cancer, pain, and immunosuppressive therapies. Symberix’s internal team and scientific/clinical/business advisors have a deep understanding of the microbiome as well as extensive drug discovery, clinical development and commercial biopharma experience. Our vision: Safe and effective pharmaceutical control of the microbiome.
1-888-653-2347 
support@leadiq.com 
